VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

Search

Medtronic PLC

Suletud

SektorTervishoid

88.96 0.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

87.4

Max

88.97

Põhinäitajad

By Trading Economics

Sissetulek

32M

1.3B

Müük

-111M

8.3B

P/E

Sektori keskmine

27.396

63.778

Aktsiakasum

1.39

Dividenditootlus

3.12

Kasumimarginaal

15.798

Töötajad

95,000

EBITDA

-40M

2.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+8.94% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.12%

2.39%

Järgmine tulemuste avaldamine

22. mai 2025

Järgmine dividendimakse kuupäev

11. apr 2025

Järgmine aktsia dividendi kuupäev (ex-date)

27. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

-5.4B

115B

Eelmine avamishind

88.37

Eelmine sulgemishind

88.96

Uudiste sentiment

By Acuity

30%

70%

57 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Medtronic PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. veebr 2025, 12:24 UTC

Tulu

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19. nov 2024, 12:27 UTC

Tulu

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27. veebr 2025, 10:30 UTC

Peamised uudised

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18. veebr 2025, 11:47 UTC

Tulu

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18. veebr 2025, 11:46 UTC

Tulu

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Adj EPS $1.39 >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Net $1.29B >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Diabetes Rev $694M >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q EPS $1.01 >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18. veebr 2025, 11:45 UTC

Tulu

Medtronic 3Q Sales $8.29B >MDT

18. veebr 2025, 10:01 UTC

Tulu
Kuumad aktsiad

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21. jaan 2025, 19:15 UTC

Peamised uudised

Medtronic Hires CFO From Renault -- Update

21. jaan 2025, 12:17 UTC

Peamised uudised

Medtronic Hires CFO From Renault

19. nov 2024, 12:12 UTC

Tulu

Medtronic Narrows FY Guidance as 2Q Tops Views

19. nov 2024, 11:46 UTC

Tulu

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19. nov 2024, 11:46 UTC

Tulu

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Adj EPS $1.26 >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Diabetes Rev $686M >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Net $1.27B >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19. nov 2024, 11:45 UTC

Tulu

Medtronic 2Q Sales $8.4B >MDT

Võrdlus sarnastega

Hinnamuutus

Medtronic PLC Prognoos

Hinnasiht

By TipRanks

8.94% tõus

12 kuu keskmine prognoos

Keskmine 96.4 USD  8.94%

Kõrge 109 USD

Madal 85 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Medtronic PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

19 ratings

9

Osta

9

Hoia

1

Müü

Tehniline skoor

By Trading Central

88.02 / 90.29Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

57 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.